9 October 2025
Novo Nordisk Acquires Akero Therapeutics to Enhance MASH Treatment Portfolio
Novo Nordisk acquires Akero for $4.7B, adding efruxifermin, a promising MASH treatment, to its portfolio. The deal includes a $0.5B contingent value right upon regulatory approval.
